• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Osteonecrosis of the jaw and bevacizumab therapy.

作者信息

Van Poznak Catherine

机构信息

University of Michigan, Ann Arbor, MI, USA.

出版信息

Breast Cancer Res Treat. 2010 Jul;122(1):189-91. doi: 10.1007/s10549-010-0933-9. Epub 2010 May 13.

DOI:10.1007/s10549-010-0933-9
PMID:20464477
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2975671/
Abstract
摘要

相似文献

1
Osteonecrosis of the jaw and bevacizumab therapy.颌骨骨坏死与贝伐单抗治疗
Breast Cancer Res Treat. 2010 Jul;122(1):189-91. doi: 10.1007/s10549-010-0933-9. Epub 2010 May 13.
2
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.贝伐珠单抗与颌骨坏死：在三项大型晚期乳腺癌前瞻性试验中与双膦酸盐治疗的发生率及相关性。
Breast Cancer Res Treat. 2010 Jul;122(1):181-8. doi: 10.1007/s10549-010-0866-3. Epub 2010 Apr 2.
3
Osteonecrosis of the jaw related to bevacizumab.与贝伐单抗相关的颌骨骨坏死
J Clin Oncol. 2008 Aug 20;26(24):4037-8. doi: 10.1200/JCO.2007.15.5424.
4
Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw.贝伐单抗（阿瓦斯汀）：一种与颌骨坏死相关的抗血管生成药物。
Gen Dent. 2011 Nov-Dec;59(6):410-3.
5
[Metastatic breast cancer--new methods of treatment].
MMW Fortschr Med. 2008 Jan 17;150(1-2):34-6. doi: 10.1007/BF03365276.
6
Bevacizumab-associated osteonecrosis of the jaw.贝伐单抗相关的颌骨骨坏死
Ann Oncol. 2008 Dec;19(12):2091-2. doi: 10.1093/annonc/mdn653. Epub 2008 Oct 31.
7
Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.乳腺癌患者颌骨坏死与双膦酸盐的使用
Expert Rev Anticancer Ther. 2009 Aug;9(8):1125-34. doi: 10.1586/era.09.74.
8
Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.颌骨骨坏死：接受双膦酸盐联合/不联合贝伐珠单抗治疗的转移性乳腺癌患者的口腔结局。
Clin Breast Cancer. 2011 Aug;11(4):252-7. doi: 10.1016/j.clbc.2011.02.001. Epub 2011 May 5.
9
Avascular osteonecrosis of the jaw as a side effect of bisphosphonate treatment.颌骨无血管性骨坏死作为双膦酸盐治疗的一种副作用。
Onkologie. 2010;33(6):288-9. doi: 10.1159/000313684. Epub 2010 May 14.
10
Osteonecrosis of the jaw.颌骨骨坏死
Endokrynol Pol. 2011 Jan-Feb;62(1):88-92.

引用本文的文献

1
Navigating Stomatologic Complications Secondary to Antineoplastic Agents-A Comprehensive Review.抗肿瘤药物继发口腔并发症的处理——综述
Cancers (Basel). 2025 Mar 21;17(7):1061. doi: 10.3390/cancers17071061.
2
Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates.颌骨坏死：甲状腺癌患者接受酪氨酸激酶抑制剂和双膦酸盐治疗的罕见但可能出现的副作用。
J Endocrinol Invest. 2021 Dec;44(12):2557-2566. doi: 10.1007/s40618-021-01634-0. Epub 2021 Jul 21.
3
The Case of Medication-Related Osteonecrosis of the Jaw Addressed from a Pathogenic Point of View. Innovative Therapeutic Strategies: Focus on the Most Recent Discoveries on Oral Mesenchymal Stem Cell-Derived Exosomes.从发病机制角度探讨药物相关性颌骨坏死病例。创新治疗策略：聚焦口腔间充质干细胞衍生外泌体的最新发现。
Pharmaceuticals (Basel). 2020 Nov 25;13(12):423. doi: 10.3390/ph13120423.
4
Review and update on drugs related to the development of osteonecrosis of the jaw.药物相关性颌骨骨坏死的研究进展与更新。
Med Oral Patol Oral Cir Bucal. 2020 Jan 1;25(1):e71-e83. doi: 10.4317/medoral.23191.
5
Meth Mouth-A Growing Epidemic in Dentistry?“ meth mouth”——牙科领域日益严重的流行病？
Dent J (Basel). 2017 Oct 30;5(4):29. doi: 10.3390/dj5040029.
6
Angiogenesis in the Development of Medication-Related Osteonecrosis of the Jaws: An Overview.颌骨药物相关性骨坏死发展中的血管生成：综述
Dent J (Basel). 2016 Dec 26;5(1):2. doi: 10.3390/dj5010002.
7
The influence of geranylgeraniol on microvessel sprouting after bisphosphonate substitution in an in vitro 3D-angiogenesis assay.在体外三维血管生成试验中，香叶基香叶醇对双膦酸盐替代后微血管芽生的影响。
Clin Oral Investig. 2017 Apr;21(3):771-778. doi: 10.1007/s00784-016-1842-z. Epub 2016 May 12.
8
Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro.类异戊二烯香叶基香叶醇：双膦酸盐治疗体外培养的内皮祖细胞后对其细胞特性的影响
Clin Oral Investig. 2015 Sep;19(7):1625-33. doi: 10.1007/s00784-014-1394-z. Epub 2015 Jan 16.
9
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).贝伐珠单抗（BVZ）联合伊立替康（CPT-11）治疗复发性中枢神经系统肿瘤患儿的相关毒性：儿科脑瘤协作组研究（PBTC-022）。
Cancer. 2013 Dec 1;119(23):4180-7. doi: 10.1002/cncr.28343. Epub 2013 Sep 19.
10
Bisphosphonates' antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay.双膦酸盐在双膦酸盐相关颌骨坏死发生发展中的抗血管生成潜能：对体内三维基质胶试验中微血管芽生的影响
Clin Oral Investig. 2014 Apr;18(3):1015-22. doi: 10.1007/s00784-013-1060-x. Epub 2013 Jul 28.

本文引用的文献

1
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.贝伐珠单抗与颌骨坏死：在三项大型晚期乳腺癌前瞻性试验中与双膦酸盐治疗的发生率及相关性。
Breast Cancer Res Treat. 2010 Jul;122(1):181-8. doi: 10.1007/s10549-010-0866-3. Epub 2010 Apr 2.
2
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.双膦酸盐相关性颌骨骨坏死癌症患者的危险因素的纵向队列研究。
J Clin Oncol. 2009 Nov 10;27(32):5356-62. doi: 10.1200/JCO.2009.21.9584. Epub 2009 Oct 5.
3
Bisphosphonate-related osteonecrosis of the jaw in randomized clinical trials.
Breast Cancer Res Treat. 2010 Jan;119(1):253-4. doi: 10.1007/s10549-009-0466-2. Epub 2009 Jul 8.
4
Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review.双膦酸盐相关和非双膦酸盐相关的颌骨骨坏死：综述
J Am Dent Assoc. 2009 Jul;140(7):864-75. doi: 10.14219/jada.archive.2009.0280.
5
Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis.颌骨骨坏死与双膦酸盐类药物在乳腺癌辅助治疗中的应用：一项荟萃分析
Breast Cancer Res Treat. 2009 Aug;116(3):433-9. doi: 10.1007/s10549-009-0432-z. Epub 2009 Jun 12.
6
Epidemiology of bisphosphonate-related osteonecrosis of the jaws: the utility of a national registry.双膦酸盐相关颌骨坏死的流行病学：国家登记处的作用
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):71-4. doi: 10.1016/j.joms.2009.01.005.
7
The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data.双膦酸盐相关颌骨坏死的发病机制：假说众多，数据匮乏。
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):61-70. doi: 10.1016/j.joms.2009.01.007.
8
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.接受抗血管生成药物治疗的转移性去势抵抗性前列腺癌患者中，颌骨骨坏死（ONJ）的发生率较高。
Cancer Invest. 2009 Feb;27(2):221-6. doi: 10.1080/07357900802208608.
9
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.美国食品药品监督管理局快速通道程序中的药物警戒与报告监督：双膦酸盐与颌骨坏死
Lancet Oncol. 2008 Dec;9(12):1166-72. doi: 10.1016/S1470-2045(08)70305-X.
10
Osteonecrosis of the jaw: who gets it, and why?颌骨骨坏死：哪些人会患病，原因是什么？
Bone. 2009 Jan;44(1):4-10. doi: 10.1016/j.bone.2008.09.012. Epub 2008 Oct 7.